Regional expansion in healthcare attracts sector investment

The Italian Government’s focus on strengthening its healthcare facilities, including restructuring of its primary healthcare system following COVID 19, has attracted Sysmex Corporation (Kobe, Japan), to build its market share through newly established direct sales and services of its haematology, urinalysis and hemostasis products as from April 2024. Offered through its affiliate Sysmex Italia SRL (formerly Sysmex Partec Italia SRL0), this expands the company’s existing portfolio of direct service provision in the fields of life sciences and industrial flow cytometry monitoring (FCM) already being provided.

Against a background of steadily growing expenditure on healthcare, with suggested forecast to exceed 180 billion euros in 2025, the company has been building its sales and services in Italy with distributors over the last 30 years or more, currently reporting a market share of over 50% in the field of haematology.

The business' strategic aims are to boost its haematology and urinalysis business by providing globally standardised product training, enhancing its Sysmex ICT-based customer support and the introduction of products with high added value. It will also be leveraging its customer base in the haematology field to increase market share in the field of hemostasis and make full use of customer feedback to capture markets in new business areas such as clinical FCM2 tests and immunochemistry. Efforts to put in place and strengthen sales and services and support systems will enable Sysmex to further contribute to the development of healthcare, the company said.

More information online